Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.6600
-0.0200 (-2.94%)
Apr 25, 2025, 4:00 PM EDT
-8.33%
Market Cap 30.49M
Revenue (ttm) n/a
Net Income (ttm) -4.09M
Shares Out 45.51M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,000
Average Volume 14,746
Open 0.6600
Previous Close 0.6800
Day's Range 0.6600 - 0.6600
52-Week Range 0.5100 - 0.8000
Beta 0.80
RSI 57.40
Earnings Date Apr 28, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company’s lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.